IWS1 and sarcoma: Targeting IWS1 specifically may circumvent the toxicity of currently available AKT inhibitors, while reducing resistance to chemo and/or radiotherapy by reversing CSC phenotypes in patients with LPS and other forms of sarcoma [46–48].